BRISTOL-MYERS SQUIBB CO (BMY)
US1101221083 - Common Stock
Overall BMY gets a fundamental rating of 5 out of 10. We evaluated BMY against 194 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BMY get a neutral evaluation. Nothing too spectacular is happening here. BMY has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BMY was profitable.
BMY had a positive operating cash flow in the past year.
Of the past 5 years BMY 4 years were profitable.
BMY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BMY has a Return On Assets of -7.75%. This is in the better half of the industry: BMY outperforms 73.96% of its industry peers.
BMY's Return On Equity of -42.34% is fine compared to the rest of the industry. BMY outperforms 61.98% of its industry peers.
BMY has a better Return On Invested Capital (13.86%) than 92.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMY is significantly below the industry average of 42.17%.
The last Return On Invested Capital (13.86%) for BMY is above the 3 year average (12.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.75% | ||
| ROE | -42.34% | ||
| ROIC | 13.86% |
ROA(3y)7.12%
ROA(5y)3.28%
ROE(3y)22.36%
ROE(5y)9.98%
ROIC(3y)12.67%
ROIC(5y)9.9%
1.3 Margins
BMY's Profit Margin has declined in the last couple of years.
BMY's Operating Margin of 23.45% is amongst the best of the industry. BMY outperforms 91.15% of its industry peers.
BMY's Operating Margin has declined in the last couple of years.
BMY's Gross Margin of 75.87% is amongst the best of the industry. BMY outperforms 83.33% of its industry peers.
In the last couple of years the Gross Margin of BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.45% | ||
| PM (TTM) | N/A | ||
| GM | 75.87% |
OM growth 3Y19.76%
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-3.95%
GM growth 3Y1.17%
GM growth 5Y1.35%
2. Health
2.1 Basic Checks
BMY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BMY has less shares outstanding
BMY has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BMY is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.16 indicates that BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
BMY has a Altman-Z score of 2.16. This is in the better half of the industry: BMY outperforms 65.63% of its industry peers.
The Debt to FCF ratio of BMY is 3.60, which is a good value as it means it would take BMY, 3.60 years of fcf income to pay off all of its debts.
BMY has a better Debt to FCF ratio (3.60) than 88.54% of its industry peers.
BMY has a Debt/Equity ratio of 2.85. This is a high value indicating a heavy dependency on external financing.
BMY's Debt to Equity ratio of 2.85 is on the low side compared to the rest of the industry. BMY is outperformed by 81.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.85 | ||
| Debt/FCF | 3.6 | ||
| Altman-Z | 2.16 |
ROIC/WACC1.66
WACC8.34%
2.3 Liquidity
BMY has a Current Ratio of 1.24. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
BMY has a Current ratio of 1.24. This is amonst the worse of the industry: BMY underperforms 82.29% of its industry peers.
BMY has a Quick Ratio of 1.09. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
BMY's Quick ratio of 1.09 is on the low side compared to the rest of the industry. BMY is outperformed by 78.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
BMY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -84.65%.
The Earnings Per Share has been growing by 13.51% on average over the past years. This is quite good.
Looking at the last year, BMY shows a small growth in Revenue. The Revenue has grown by 5.56% in the last year.
BMY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.81% yearly.
EPS 1Y (TTM)-84.65%
EPS 3Y5.21%
EPS 5Y13.51%
EPS Q2Q%-10%
Revenue 1Y (TTM)5.56%
Revenue growth 3Y1.91%
Revenue growth 5Y14.81%
Sales Q2Q%8.44%
3.2 Future
The Earnings Per Share is expected to decrease by -3.44% on average over the next years.
BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.54% yearly.
EPS Next Y-87.81%
EPS Next 2Y-2.84%
EPS Next 3Y-4.98%
EPS Next 5Y-3.44%
Revenue Next Year6.18%
Revenue Next 2Y2.37%
Revenue Next 3Y-0.43%
Revenue Next 5Y-1.54%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BMY is valuated quite expensively with a Price/Earnings ratio of 50.44.
Based on the Price/Earnings ratio, BMY is valued a bit cheaper than the industry average as 79.17% of the companies are valued more expensively.
BMY is valuated expensively when we compare the Price/Earnings ratio to 29.12, which is the current average of the S&P500 Index.
BMY is valuated reasonably with a Price/Forward Earnings ratio of 8.34.
Based on the Price/Forward Earnings ratio, BMY is valued cheaper than 90.63% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BMY to the average of the S&P500 Index (23.79), we can say BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.44 | ||
| Fwd PE | 8.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMY is valued cheaper than 91.15% of the companies in the same industry.
BMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMY is cheaper than 93.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.67 | ||
| EV/EBITDA | 7.63 |
4.3 Compensation for Growth
BMY has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as BMY's earnings are expected to decrease with -4.98% in the coming years.
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y-2.84%
EPS Next 3Y-4.98%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.39%, BMY is a good candidate for dividend investing.
BMY's Dividend Yield is rather good when compared to the industry average which is at 4.14. BMY pays more dividend than 96.35% of the companies in the same industry.
BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.21.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.39% |
5.2 History
On average, the dividend of BMY grows each year by 7.57%, which is quite nice.
BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of BMY decreased in the last 3 years.
Dividend Growth(5Y)7.57%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
The earnings of BMY are negative and hence is the payout ratio. BMY will probably not be able to sustain this dividend level.
DP-66.2%
EPS Next 2Y-2.84%
EPS Next 3Y-4.98%
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (11/12/2024, 7:00:00 PM)
After market: 59 -0.02 (-0.03%)59.02
-0.8 (-1.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap119.70B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.39% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.44 | ||
| Fwd PE | 8.34 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)3.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.75% | ||
| ROE | -42.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 23.45% | ||
| PM (TTM) | N/A | ||
| GM | 75.87% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.85 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-84.65%
EPS 3Y5.21%
EPS 5Y
EPS Q2Q%
EPS Next Y-87.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.56%
Revenue growth 3Y1.91%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y